WO2021215717A1 - 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 - Google Patents
혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 Download PDFInfo
- Publication number
- WO2021215717A1 WO2021215717A1 PCT/KR2021/004479 KR2021004479W WO2021215717A1 WO 2021215717 A1 WO2021215717 A1 WO 2021215717A1 KR 2021004479 W KR2021004479 W KR 2021004479W WO 2021215717 A1 WO2021215717 A1 WO 2021215717A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vip
- microorganism
- lactobacillus
- promoter
- protease
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 84
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 title claims description 90
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 title claims description 75
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 title claims 9
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 21
- 230000006378 damage Effects 0.000 claims abstract description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 240000001929 Lactobacillus brevis Species 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 19
- 101150005793 ribB gene Proteins 0.000 claims description 18
- 101150073450 ribE gene Proteins 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 15
- 241000186660 Lactobacillus Species 0.000 claims description 14
- 229940039696 lactobacillus Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 claims description 9
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 claims description 9
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 9
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 claims description 9
- 101150072314 thyA gene Proteins 0.000 claims description 9
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 7
- 241000194036 Lactococcus Species 0.000 claims description 5
- 241000194035 Lactococcus lactis Species 0.000 claims description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- 101150117187 glmS gene Proteins 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 1
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 1
- 101150084623 vip gene Proteins 0.000 abstract description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 76
- 101150007310 htrA gene Proteins 0.000 description 15
- 101150064613 pepN gene Proteins 0.000 description 14
- 101150018266 degP gene Proteins 0.000 description 13
- 238000011282 treatment Methods 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 7
- 239000002981 blocking agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- -1 for example Proteins 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000192001 Pediococcus Species 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 101150043276 Lon gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960002871 tenoxicam Drugs 0.000 description 3
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 101150074451 clpP gene Proteins 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 2
- 229960000514 ethenzamide Drugs 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940124829 interleukin-23 Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 229960005222 phenazone Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 2
- 229950010302 tiaramide Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229950004227 zaltoprofen Drugs 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- WEEYASWRWODDTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl]-2,3-dihydro-1,4-benzothiazine-7-carbonyl]amino]hexanedioic acid Chemical compound C1CSC2=CC(C(=O)N[C@@H](CCCC(O)=O)C(O)=O)=CC=C2N1CC1=NC2=C(N)N=C(N)N=C2N=C1 WEEYASWRWODDTJ-ZDUSSCGKSA-N 0.000 description 1
- XCRAFTGAMMSJLO-UHFFFAOYSA-K 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxypropane-1,2,3-tricarboxylate;1,3,7-trimethylpurine-2,6-dione Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.CN1C(C)=CC(=O)N1C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C XCRAFTGAMMSJLO-UHFFFAOYSA-K 0.000 description 1
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
- MOUZYBYTICOTFQ-UHFFFAOYSA-N 3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-n,n-diethylpropan-1-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 MOUZYBYTICOTFQ-UHFFFAOYSA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 101100540498 Arabidopsis thaliana VIP4 gene Proteins 0.000 description 1
- 101100540499 Arabidopsis thaliana VIP5 gene Proteins 0.000 description 1
- 101100317003 Arabidopsis thaliana VIP6 gene Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020003338 D-alanine-D-alanine ligase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090001031 Glutamine-fructose-6-phosphate transaminase (isomerizing) Proteins 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 101000953492 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Proteins 0.000 description 1
- 101000953488 Homo sapiens Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 Proteins 0.000 description 1
- 101000760243 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 45 Proteins 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037739 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Human genes 0.000 description 1
- 102100037736 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 102000015930 Lon proteases Human genes 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101500027964 Mus musculus Vasoactive intestinal peptide Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 108010023294 Protease La Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102100024718 Ubiquitin carboxyl-terminal hydrolase 45 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101150077913 VIP3 gene Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000963 caseinolytic effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- 229940042902 flumethasone pivalate Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- MMHHPKCJJIFLBQ-QFIPXVFZSA-N methyl (2s)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[6-(dimethylamino)-1-methyl-2,4-dioxoquinazolin-3-yl]phenyl]propanoate Chemical compound N([C@@H](CC=1C=CC(=CC=1)N1C(C2=CC(=CC=C2N(C)C1=O)N(C)C)=O)C(=O)OC)C(=O)C1=C(Cl)C=CC=C1Cl MMHHPKCJJIFLBQ-QFIPXVFZSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
Definitions
- the present disclosure relates to microorganisms expressing vasoactive intestinal peptide (VIP), and compositions for preventing or treating diseases causing damage to the gastrointestinal tract, including the microorganisms.
- VIP vasoactive intestinal peptide
- VIP is a peptide hormone that is vasoactive in the intestine.
- VIP is a peptide with 28 amino acid residues belonging to the ligands of the glucagon/secretin superfamily, class II G protein-coupled receptors.
- Korean Patent Application Laid-Open No. 2014-0000620 discloses Lactobacillus and its irritable bowel syndrome (IBD) treatment use to increase VIP levels in the enteric nervous system. It is a strain screened in nature and is not a recombinant microorganism.
- IBD irritable bowel syndrome
- Cid-Open Patent No. 108753670 discloses a recombinant microorganism Lactococcus lactis NZ9000 that expresses VIP and is rich in selenium nanoparticles (SeNP) in cells. Since selenium is present in cells in the form of nanoparticles, this recombinant microorganism solves the problems of strong toxicity, low bioavailability, high environmental pollution, and high production cost of selenium when used as a selenium additive while simultaneously solving the problems of antibacterial peptide It is described that it can solve the problem of antibiotic residue by secreting phosphorus VIP. In addition, the pNZ8148 plasmid of the NICE® Lactococcus lactis expression system was used for VIP secretion expression.
- An object of the present disclosure is to provide a recombinant Lactobacillus ( Lactobacillus ) genus microorganism expressing exogenous VIP.
- Another object is to provide a recombinant lactic acid bacterium expressing exogenous VIP under a constitutive promoter.
- Another object is to provide a composition for preventing or treating a disease causing damage to the gastrointestinal tract in humans comprising the microorganism.
- One aspect of the present disclosure is a promoter, and a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to the promoter is introduced and a protease is inactivated (inactivated) recombinant As a microorganism, Lactobacillus ( Lactobacillus ) It provides a recombinant microorganism of the genus.
- VIP vasoactive intestinal peptide
- Another aspect of the present disclosure is a recombinant microorganism into which a constitutive promoter and a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to the promoter are introduced and the protease is inactivated, It provides a recombinant microorganism that is a lactic acid bacterium.
- VIP vasoactive intestinal peptide
- Another aspect of the present disclosure is a recombinant microorganism into which a promoter and a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to the promoter are introduced and the protease is inactivated, which is a lactic acid bacterium.
- VIP vasoactive intestinal peptide
- VIP or “VIP protein” or “VIP polypeptide” refers to a biologically active polypeptide having one or more of the biological activities as described herein.
- the q25 region of chromosome 6 on the human genome encodes a member of the secretin family that is 170 amino acids in length.
- This member of 170 amino acids in length is post-translationally truncated to form a vasoactive intestinal peptide (VIP).
- VIP polypeptide lowers blood pressure, increases vasodilation of blood vessel walls, relaxes smooth muscle in respiratory and gastrointestinal tissues, decreases Th1 response as well as immune response through promotion of Th2. It functions to reduce the blood flow, to modulate innate and acquired immune responses, or to promote the secretion of electrolytes in the intestine.
- VIPs have been shown to be active as neurotransmitters in the central nervous system and in communication with lymphocytes.
- VIP 1 R The bioactivity of VIP is transmitted through three known receptors: VIP 1 R, VIP 2 R, and PAC 1 R. These receptors are known to cause cAMP enrichment as well as the production of intracellular calcium. Like VIP, their affinity for secretins depends on the subtype and the amino acid sequence of the ligand. Human natural VIPs have a short half-life, with a half-life of about 2 minutes in the bloodstream.
- VIPs referred to herein include variants that mimic the function of native VIPs.
- the variants include those having an increased half-life than native VIP and equivalent or greater bioactivity compared to native VIP.
- VIP includes, but is not limited to, human VIP, recombinant human VIP, murine VIP, and/or recombinant mouse VIP.
- the VIP has 50% or more, 60% or more, 70% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 1 it could be
- the VIP may have an amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, and 9, respectively.
- VIP of SEQ ID NO: 1 is a human-derived natural VIP.
- VIPs having the amino acid sequences of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, and 9 are the human-derived native VIP variants VIP1, VIP2, VIP3, VIP4, VIP5, VIP6, VIP7, and VIP8.
- the VIP polypeptides can be isolated from a variety of sources, such as human tissue or other sources, or prepared by recombinant or synthetic methods.
- VIP polypeptide also includes variants of VIP polypeptides.
- a VIP may be modified in such a way that it forms a chimeric molecule comprising the VIP fused to another heterologous polypeptide or amino acid sequence.
- protease is a generic term for enzymes that degrade proteins, and may include any type known in the art without particular limitation.
- auxotroph refers to a strain that cannot grow in a synthetic medium consisting only of inorganic salts and a carbon source and grows only by supplementing one or more nutrients, Any known kind may be included without particular limitation.
- the microorganism according to an aspect of the present disclosure is a recombinant microorganism into which a promoter and a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to the promoter are introduced, and the protease is inactivated. will be.
- VIP vasoactive intestinal peptide
- the microorganism according to another aspect of the present disclosure is a recombinant microorganism into which a constitutive promoter and a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to the promoter are introduced and the protease is inactivated, and lactic acid bacteria It is a recombinant microorganism that is
- the lactic acid bacteria is Lactobacillus ( Lactobacillus ), Lactococcus ( Lactococcus ), Bifidobacteria ( Bifidobacteria ), Streptococcus ( Streptococcus ), Leuconostoc ( Leuconostoc ), Weissella ), or Pediococcus ( Pediococcus ), Pediococcus ( Pediococcus ) Caucus ( Enterococcus ) genus, particularly Lactobacillus ( Lactobacillus ), Lactococcus ( Lactococcus ) may be belonging to the genus, for example, Lactobacillus paracasei , Lactobacillus brevis , Lactobacillus plantarum or Lactococcus lactis may be one.
- the microorganism of the genus Lactobacillus may be Lactobacillus paracasei , Lactobacillus brevis , or Lactobacillus plantarum .
- it may be Lactobacillus plantarum LMT1-9 (KCTC 13421BP), Lactobacillus paracasei LMT1-21 (KCTC 13422BP), or Lactobacillus brevis LMT1-46 (KCTC 13423BP).
- the promoter may be a constitutive promoter.
- the promoter may have transcription initiation efficiency in lactic acid bacteria equal to or greater than that of a conventional promoter, for example, the P11 promoter.
- the promoter may also be an inducible promoter.
- the inducible promoter may be, for example, a Nisin inducible promoter.
- the promoter may be PR4 derived from Lactobacillus paracasei comprising the polynucleotide of SEQ ID NO: 10.
- PR4 may be composed of the nucleotide sequence of SEQ ID NO: 11.
- the microorganism according to the present disclosure is characterized in that a foreign gene encoding VIP is introduced.
- the introduction may be by transformation, transduction, transfection or electroporation.
- the introduced foreign gene may be integrated into the genome of the host cell or may exist without being integrated.
- the foreign gene may be integrated into the genome of the host cell.
- the microorganism according to the present disclosure is characterized in that the protease is inactivated.
- the gene encoding the protease may be deleted (deleted). “Deletion” includes deletion of at least a portion, eg, all or part, of a gene.
- the gene encoding the protease is replaced with a foreign gene encoding a vasoactive intestinal peptide (VIP) operably linked to a promoter, whereby the introduction of the foreign VIP gene and the deletion of the protease gene can be implemented simultaneously.
- VIP vasoactive intestinal peptide
- Replacement includes replacement of at least a portion, eg, all or part, of a gene.
- protase may include any type known in the art without particular limitation.
- HtrA and/or PepN may be HtrA.
- the htrA gene may be an L. brevis htrA gene, particularly SEQ ID NO: 14.
- the pepN gene may be an L. brevis pepN gene, particularly SEQ ID NO: 15.
- the clpP gene may be L.
- brevis It may be a clpP gene, particularly SEQ ID NO: 16.
- the lon gene may be an L. brevis lon gene, particularly SEQ ID NO: 17.
- the protease is not expressed and thus the foreign VIP protein is prevented from being degraded. , can increase the yield or productivity of the VIP protein According to one embodiment, when HtrA is not expressed, the productivity of the VIP protein can be greatly increased.
- the recombinant microorganism may further include a signal sequence operably linked between the promoter and the foreign gene.
- a signal sequence operably linked between the promoter and the foreign gene.
- the signal sequence may encode SP4 (SEQ ID NO: 12) derived from Lactobacillus paracasei.
- SP4 may have the nucleotide sequence of SEQ ID NO:13.
- the microorganism may be to secrete VIP out of the cell.
- the recombinant microorganism may be an auxotroph.
- the auxotroph is, for example, one or more genes selected from the group consisting of Riboflavin biosynthesis protein gene (ribB), Thymidylate synthase gene (thyA) and Glutamine--fructose-6-phosphate aminotransferase gene (glmS), for example, ribB and / or thyA, for example, ribB may be deleted, but there is no particular limitation.
- the ribB may be L. brevis ribB, in particular of SEQ ID NO: 18.
- thyA may be L. brevis thyA, particularly of SEQ ID NO: 19.
- the glmS may be L.
- deletion includes deletion of at least a portion, eg, all or part, of a gene.
- compositions for use in preventing or treating a disease causing damage to the gastrointestinal tract comprising the above-mentioned microorganism.
- the disease may be one that causes inflammation of the gastrointestinal tract.
- the disease may be at least one selected from the group consisting of inflammatory bowel disease (IBD), and colitis.
- IBD inflammatory bowel disease
- colitis may be ulcerative colitis or Crohn's disease.
- the composition may include a pharmaceutically or food acceptable carrier, excipient or diluent.
- the pharmaceutically or food acceptable carrier may be any standard such as a phosphate buffered saline solution, a 5% aqueous solution of dextrose and an emulsion (eg, oil/water or water/oil emulsion).
- emulsion eg, oil/water or water/oil emulsion
- excipients include adjuvants, binders, fillers, diluents, disintegrants, emulsifiers, wetting agents, lubricants, glidants, sweetening agents, flavoring and coloring agents.
- the preferred pharmaceutical or food carrier depends on the intended mode of administration of the active agent.
- Typical modes of administration include enteral (eg, oral) administration.
- the composition may be in unit dosage form.
- the composition may have an oral dosage form.
- the composition may be a food or pharmaceutical composition.
- the composition may include a dried product of the microorganism.
- the composition may include a medium for the microorganism.
- pharmaceutically acceptable or acceptable for food refers to substantially not causing adverse reactions when administered to a subject.
- the side effect may be toxic, allergic, or an immune response.
- kits for use in preventing or treating a disease causing damage to the gastrointestinal tract comprising the above recombinant microorganism and a drug for treating other gastrointestinal damaging diseases.
- the recombinant microorganism is as described above.
- the recombinant microorganism may be in the form of the composition described above.
- the kit may include instructions for using recombinant microorganisms and drugs for treating other diseases of the gastrointestinal tract to prevent or treat diseases that cause damage to the gastrointestinal tract.
- the drug for treating other diseases that damage the gastrointestinal tract includes any drug that treats diseases that damage the gastrointestinal tract, for example, inflammatory bowel disease.
- Drugs for treating diseases of the gastrointestinal tract may include the following drugs:
- methotrexate methotrexate, cyclophosphamide, MX-68, atiprimod dihydrochloride, BMS-188667, CKD-461, rimexolone, cyclosporine, tacrolimus, gusperimus, azathiopurine, antilymphocyte stimulating factor, freeze-dukin sulfonated normal immunoglobulin, erythropoietin, colony, etc.
- TNF-alpha-receptor IgG-Fc fusion protein etanercept
- infliximab adalimumab
- certolizumab pegol certolizumab pegol
- golimumab golimumab
- PASSTNF- ⁇ soluble TNF- ⁇ receptor
- TNF- ⁇ binding protein anti-TNF- ⁇ antibody
- CDP571 CDP571 and the like.
- natalizumab vedolizumab, AJM300, TRK-170, E-6007, etc.
- NSAIDs non-steroidal anti-inflammatory drugs
- benzbromarone allopurinol, sodium aurothiomalate, hyaluronate sodium, sodium salicylate, salicylic acid, atropine, scopolamine, levorphanol, oxymorphone or its salts, etc.
- salicylic acid derivatives eg celecoxib, aspirin
- etoricoxib etoricoxib
- valdecoxib etoricoxib
- diclofenac sodium indomethacin
- loxoprofen etc.
- the description of the microorganism is also applicable to the composition.
- Another aspect provides a method for preventing or treating a disease causing damage to the gastrointestinal tract, comprising administering to the subject an amount of the microorganism that is effective for preventing or treating the disease causing damage to the gastrointestinal tract.
- the method may further comprise administering to the subject an amount of a TNF-alpha blocker effective to prevent or treat a disease causing damage to the gastrointestinal tract.
- the step of administering the TNF-alpha blocking agent to the subject may be performed simultaneously with, before, or after the step of administering the microorganism to the subject.
- the TNF-alpha blocking agent may be administered by the same or different route as the route to which the microorganism is administered.
- the TNF-alpha blocking agent may be administered orally or parenterally.
- the parenteral may be an injection such as vascular injection, intraperitoneal injection, or subcutaneous injection.
- the TNF-alpha blocking agent may be administered intraperitoneally, and the microorganism may be administered orally.
- the TNF-alpha blocking agent may be administered intraperitoneally after the microorganism is orally administered.
- the TNF-alpha blocking agent may be administered in an amount of 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 40 mg, 10 mg to 50 mg, or 20 mg to 50 mg per one administration.
- the disease may cause inflammation of the gastrointestinal tract.
- the diseases include inflammatory intestinal disease, autoimmune disease, damage to the gastrointestinal tract by radiation or graft versus host disease (GVHD), inflammatory bowel disease : IBD), and colitis including chronic colitis may be at least one selected from the group consisting of.
- the inflammatory bowel disease may be ulcerative colitis or Crohn's disease.
- the "administering or administration” refers to administering the microorganism to a physiological system (individual or in vivo, in vitro, or ex vivo cells, tissues and organs), a composition comprising the microorganism, or a therapeutic agent. Indicates the act of giving therapeutic treatment. Accordingly, in the method, the microorganism may be in the form of the composition described above.
- An acceptable route of administration to the human body may be oral, or mucosal (eg, intestinal mucosa, oral mucosa or Bucal).
- the administration may be administered in combination with an additional therapeutic agent.
- the combination administration includes either simultaneous or sequential order.
- treatment refers to prophylactic treatment or therapeutic treatment.
- treatment refers to administration of a microorganism or composition to an individual for therapeutic or prophylactic purposes.
- a “therapeutic” treatment is a treatment administered to a subject exhibiting pathological signs or symptoms to reduce or eliminate the signs or symptoms. Signs or symptoms may be biochemical, cellular, histological, functional or physical, subjective or objective.
- a “prophylactic” treatment is a treatment administered to a subject that does not show signs of a disease or only shows early signs of a disease in order to reduce the risk of developing a pathology.
- the microorganisms or compositions described herein can be provided as a prophylactic treatment to reduce the likelihood of developing a pathology, or to minimize the severity of the pathology if it does occur.
- terapéuticaally effective amount refers to an amount sufficient to carry out the stated purpose.
- An effective amount can be determined empirically. The effective amount may be determined, for example, depending on the extent to which the microorganism secretes VIP into the extracellular space. For example, for a person having a body weight of 60 kg, it may be the number of the microorganisms capable of secreting 0.01 to 300 mg, or 0.5 to 100 mg of VIP per day.
- the subject may be a mammal.
- the mammal may be a human, horse, pig, cow, dog, cat, monkey, chimpanzee, sheep, or goat.
- microorganism and/or composition is also applicable to the method.
- the recombinant microorganism according to the present disclosure can not only produce and secrete VIP with higher productivity, but also exhibit high environmental safety, thereby more effectively preventing or treating diseases that cause damage to the gastrointestinal tract.
- FIG. 1a and 1b are schematic diagrams showing a genetically engineered site of a recombinant microorganism according to an embodiment.
- Figures 2a and 2b is a view confirming the production of a recombinant microorganism with improved VIP productivity according to an embodiment.
- Figures 3a and 3b is a view showing that the VIP productivity of the recombinant microorganism according to one embodiment is improved.
- 4a and 4b are views confirming the production of recombinant microorganisms with improved environmental safety according to an embodiment.
- 5A and 5B are views showing that the environmental safety of recombinant microorganisms according to an embodiment is improved.
- FIG. 6 is a view showing that a recombinant microorganism according to an embodiment exhibits an IBD therapeutic effect in an animal model.
- Lactobacillus brevis LMT1-46 (KCTC 13423BP)
- KCTC 13423BP a homologous recombination genetic engineering method commonly used in lactic acid bacteria
- D-Ala-D-Ala ligase as a broad host-range counterselection marker in vancomycin resistant lactic acid
- a recombinant microorganism expressing exogenous VIP was prepared.
- FIGS. 1a and 1b schematically show the genetically engineered site of the microorganism according to this example.
- Figure 1a shows the process of replacing the protease gene (htrA or pepN) with the VIP gene to improve VIP productivity.
- a signal peptide that helps to secrete back and forth of VIP and a tag for detection were included in one cassette.
- the protase gene is L. brevis htrA (SEQ ID NO: 14) or L. brevis pepN (SEQ ID NO: 15).
- Figure 1b shows the process of forming a auxotroph to promote environmental safety, a method of removing some regions of the target gene.
- the target gene is L. brevis ribB (SEQ ID NO: 18).
- 1A and 1B has the following meaning: P: Promoter, SP: Signal Peptide, UTR: Untranslated Region, VIP: Vasoactive Intestinal Peptide), A: L. brevis ribB, B: L. brevis htrA or L. brevis pepN.
- FIGS. 2A and 2B are schematic diagrams (left) showing the replacement of the protase genes htrA (FIG. 2A) and pepN (FIG. 2B) by the VIP expression cassette, respectively, and the size of the bands generated by recombinant microorganisms therefrom is a gel image (right) showing that ⁇ has changed as intended.
- FIGS. 2A and 2B it was confirmed that recombinant microorganisms were generated in which the protase genes htrA and pepN were replaced with VIP expression cassettes, respectively.
- the band size of the PCR product was 1.5 kb in the wild type, and when the htrA region was replaced with the VIP expression cassette, the band size was 920 bp.
- the wild-type PCR product had a band size of 2 kB, and when the pepN region was replaced with a VIP expression cassette, the band size was 1.3 kb.
- each abbreviation is as defined in Example 1, and WT in the gel image means wild type.
- Example 3 Evaluation of VIP productivity of recombinant microorganisms
- Example 1 In order to confirm whether the VIP productivity of the recombinant microorganism was improved, evaluation was performed to confirm the VIP expression level of the strains prepared in Example 1.
- the stock of the prepared strain was streaked on an MRS plate and cultured for 3 days at 37°C. Here, single colonies were picked and cultured with shaking at 37°C in MRS liquid medium for 24 hours. This was inoculated to 25ml MRS so that OD 600 became 0.1, and then cultured with shaking at 37°C for 16 hours. 10ml of the strain culture medium was extracted and centrifuged at 4000rpm for 10 minutes, and only the supernatant was extracted, 1ml of TCA (Tricholoacetic acid) was added, and treated at 4°C for 30 minutes or more.
- TCA Tricholoacetic acid
- FIG. 3a is a graph showing a gel image (left) showing VIP expressed from a recombinant strain in which htrA and/or ribB is deleted and quantifying the expression level of VIP (right).
- 3b is a graph showing the expression level of VIP expressed from a recombinant strain in which pepN is deleted.
- the protase gene of L. brevis was deleted, the expression level of VIP, an effective substance, was increased.
- the expression level of the target substance, VIP was increased three-fold or more compared to that in which other genes were deleted.
- FIGS. 4A and 4B are schematic diagrams (left) of a recombinant microorganism in which rib and thyA are deleted, respectively, and a gel image (right) showing that the size of the band was changed as intended by the generation of the recombinant microorganism therefrom.
- FIGS. 4A and 4B each abbreviation is as defined in Example 1, and WT in the gel image means wild type.
- FIGS. 4A and 4B it was confirmed that recombinant microorganisms in which ribB and thyA were deleted were generated.
- the band size of the PCR product was 1.0 kb in the wild type, and when the ribB region was deleted, the band size was 500 bp.
- the wild type was 250 bp, and no band was observed in the strain in which ribB was deleted.
- the band size of the PCR product was 700 bp in the wild type, and when a part of the thyA region was deleted, the band size was 500 bp.
- a growth test was performed to determine the growth pattern of the strain prepared in Example 1.
- the stock of the prepared strain was streaked on an MRS plate and cultured for 3 days at 37°C. Here, single colonies were picked and cultured in MRS broth at 37° C. for 24 hours with shaking (230 rpm).
- 1 ml of the culture medium was extracted and centrifuged at 13000 rpm for 1 minute.
- the OD 600 was measured and inoculated to 25ml of a minimal medium for lactic acid bacteria called SDM (Semi-defined media), which is an environment in which growth can be inhibited, so that the OD 600 becomes 0.0025. It was cultured for 40 hours under shaking culture (230 rpm) conditions at 37° C., and the values measured for OD 600 at 15, 17, 20, 22, 24, and 40 hours after inoculation are shown as graphs.
- FIGS. 5A and 5B are graphs showing the growth patterns of ribB-deleted recombinant lactic acid bacteria (FIG. 5A) and thyA-deleted recombinant lactic acid bacteria (FIG. 5B).
- WT means wild type. It was confirmed from Figures 5a and 5b that the auxotrophic lactic acid bacteria cause growth inhibition in nutrient-deficient medium conditions.
- Example 6 In vivo efficacy: IBD animal model experiment
- the transgenic strain was orally administered to a DSS (dextran sulfate sodium)-induced mouse intestinal inflammation model, and then the survival rate or DAI (disease activity index) score was checked.
- DSS extran sulfate sodium
- DAI disease activity index
- the culture supernatant was removed by centrifugation at 4000rpm for 10 minutes, and the recovered strain was suspended in 1x PBS so that it could be administered at 1x10 9 cfu per animal once.
- the strain administration was performed once a day, for a total of 16 days.
- the treatment efficacy experiment was started by setting the first strain administration day to Day-9, and from Day 0 to Day 5, 2% DSS was treated with a negative number in all groups except for the PBS group, and euthanasia was performed on Day 8.
- the DAI score was calculated by checking the weight loss, hair bristles, the degree of movement of the animals and the presence of diarrhea every 2 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
명칭 | 서열 | 서열번호 |
1-46 pepN icF | AGC AAC CTT TGA CCT AGC | 21 |
1-46 pepN icR | AAT TCC ATA TCA CCA CCC AC | 22 |
pepN orf cF | CCC GAT GGC CTT ACA AC | 23 |
pepN orf cR | GGA ACG GCT GTC CAT TAG | 24 |
1-46 htrA insert cF | CTA AAT GAG GAG GGT TCG CG | 25 |
1-46 htrA insert cR | AAG CTG GCG CTT TCA TTC C | 26 |
1-46 htrA ORF cF | ACC TCT AAC GTC AAC GTC | 27 |
1-46 htrA ORF cR | AGT TCC CAG GGT TAA TCG | 28 |
명칭 | 서열 | 서열번호 |
1-46 ribB orf cF | TAA CCG CAG TGA CTG AC | 29 |
1-46 ribB orf cR | AGC TGA TAC ATC AAA GGT C | 30 |
1-46 ribB icF | AGC ATT GTG TTA TCA GC | 31 |
1-46 ribB icR | GCA GCA TTG GTA GCA AC | 32 |
LbthyA-UP-cF3 | GTG TGG CAA GGT GGC AAA GCC A | 33 |
LbthyA-DN-cR1 | CCG ATC TAC AGG CCC AAC TCG ATG A | 34 |
Claims (15)
- 프로모터, 및 상기 프로모터와 작동가능하게 연결된 혈관작동성 장 펩티드(VIP)를 코딩하는 외래 유전자가 도입되고(introduced) 프로테이즈(protease)가 불활성화되어 있는(inactivated) 재조합 미생물로서, 락토바실러스(Lactobacillus) 속인 것인 재조합 미생물.
- 청구항 1에 있어서, 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 브레비스(Lactobacillus brevis), 또는 락토바실러스 플란타럼(Lactobacillus plantarum)인 것인 미생물.
- 구성적 프로모터(constitutive promoter), 및 상기 프로모터와 작동가능하게 연결된 혈관작동성 장 펩티드(VIP)를 코딩하는 외래 유전자가 도입되고 프로테이즈가 불활성화되어 있는 재조합 미생물로서, 유산균인 것인 재조합 미생물.
- 청구항 3에 있어서, 상기 유산균은 락토바실러스(Lactobacillus) 속, 또는 락토코커스(Lactococcus) 속인 것인 미생물.
- 청구항 4에 있어서, 상기 유산균은 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 브레비스(Lactobacillus brevis), 락토바실러스 플란타럼(Lactobacillus plantarum), 또는 락토코커스 락티스(Lactococcus lactis)인 것인 미생물.
- 청구항 1 내지 5 중 어느 한 항에 있어서, 상기 프로모터와 상기 외래 유전자 사이에 작동가능하게 연결되어 있는 신호 서열을 추가로 포함하는 것인 미생물.
- 청구항 1 내지 5 중 어느 한 항에 있어서, 프로테이즈를 코딩하는 유전자가 결실되어 있는(deleted) 미생물.
- 청구항 7에 있어서, 프로테이즈를 코딩하는 유전자가 프로모터와 작동가능하게 연결된 혈관작동성 장 펩티드(VIP)를 코딩하는 외래 유전자로 대체된(replaced) 미생물.
- 청구항 1 내지 5 중 어느 한 항에 있어서, 프로테이즈가 HtrA, PepN, ClpP 및 Lon으로 구성된 군으로부터 선택되는 하나 이상의 것인 미생물.
- 청구항 1 내지 5 중 어느 한 항에 있어서, 영양요구주(auxotroph)인 미생물.
- 청구항 10에 있어서, ribB, thyA 및 glmS로 구성된 군으로부터 선택되는 하나 이상의 유전자가 결실된 미생물.
- 프로모터, 및 상기 프로모터와 작동가능하게 연결된 혈관작동성 장 펩티드(VIP)를 코딩하는 외래 유전자가 도입되고 프로테이즈가 불활성화되어 있는 재조합 미생물로서, 유산균인 것인 재조합 미생물을 포함하는, 사람에서 위장관(gastrointestinal tract)의 손상을 야기하는 질환을 예방 또는 치료하기 위한 조성물.
- 청구항 12에 있어서, 상기 질환은 위장관 염증을 야기하는 것인 조성물.
- 청구항 13에 있어서, 상기 질환은 염증성 장질환(IBD), 및 대장염(colitis)으로 이루어진 군으로부터 선택된 하나 이상인 것인 조성물.
- 청구항 14에 있어서, 상기 염증성 장질환은 궤양성 대장염(ulcerative colitis), 또는 크론병(Crohn's disease)인 것인 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180029642.2A CN115916982A (zh) | 2020-04-20 | 2021-04-09 | 表达血管活性肠肽的微生物及其用途 |
AU2021258959A AU2021258959A1 (en) | 2020-04-20 | 2021-04-09 | Microorganism expressing vasoactive intestinal peptide, and use thereof |
JP2022563907A JP2023523214A (ja) | 2020-04-20 | 2021-04-09 | 血管作動性腸ペプチドを発現する微生物、及びその用途 |
EP21793347.2A EP4144847A4 (en) | 2020-04-20 | 2021-04-09 | MICROORGANISM EXPRESSING VASOACTIVE INTESTINAL PEPTIDE AND ITS USE |
CA3180666A CA3180666A1 (en) | 2020-04-20 | 2021-04-09 | Microorganism expressing vasoactive intestinal peptide, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200047660A KR20210129516A (ko) | 2020-04-20 | 2020-04-20 | 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 |
KR10-2020-0047660 | 2020-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021215717A1 true WO2021215717A1 (ko) | 2021-10-28 |
Family
ID=78232760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/004479 WO2021215717A1 (ko) | 2020-04-20 | 2021-04-09 | 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4144847A4 (ko) |
JP (1) | JP2023523214A (ko) |
KR (1) | KR20210129516A (ko) |
CN (1) | CN115916982A (ko) |
AU (1) | AU2021258959A1 (ko) |
CA (1) | CA3180666A1 (ko) |
WO (1) | WO2021215717A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096123A1 (ja) * | 2022-11-04 | 2024-05-10 | 株式会社バイオパレット | 遺伝子が改変された微生物およびその生産方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006262724A (ja) * | 2005-03-22 | 2006-10-05 | Kobe Univ | タンパク質高発現乳酸菌 |
KR20120062777A (ko) * | 2009-08-14 | 2012-06-14 | 파세비오 파마수티컬스 인코포레이티드 | 변형된 혈관활성 장 펩티드 |
KR20140000620A (ko) | 2010-05-28 | 2014-01-03 | 꽁빠니 자베 다노느 | 장신경계의 개선을 위한 프로바이오틱 균주의 용도 |
KR20150095717A (ko) * | 2012-12-18 | 2015-08-21 | 꽁빠니 자베 다노느 | 비피도박테리움 아니말리스 아종 아니말리스 균주 |
CN108753670A (zh) | 2018-05-28 | 2018-11-06 | 西北工业大学 | 多功能复合微生态制剂纳米硒-重组表达血管活性肠肽-乳酸乳球菌及制备方法 |
KR101992345B1 (ko) * | 2017-12-29 | 2019-09-27 | (주)메디톡스 | 프로모터 폴리뉴클레오티드, 신호 폴리펩티드 및 그의 용도 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101910808B1 (ko) * | 2016-11-28 | 2018-10-24 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질 및 이의 항암 용도 |
-
2020
- 2020-04-20 KR KR1020200047660A patent/KR20210129516A/ko not_active Application Discontinuation
-
2021
- 2021-04-09 CA CA3180666A patent/CA3180666A1/en active Pending
- 2021-04-09 AU AU2021258959A patent/AU2021258959A1/en active Pending
- 2021-04-09 JP JP2022563907A patent/JP2023523214A/ja active Pending
- 2021-04-09 CN CN202180029642.2A patent/CN115916982A/zh active Pending
- 2021-04-09 WO PCT/KR2021/004479 patent/WO2021215717A1/ko unknown
- 2021-04-09 EP EP21793347.2A patent/EP4144847A4/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006262724A (ja) * | 2005-03-22 | 2006-10-05 | Kobe Univ | タンパク質高発現乳酸菌 |
KR20120062777A (ko) * | 2009-08-14 | 2012-06-14 | 파세비오 파마수티컬스 인코포레이티드 | 변형된 혈관활성 장 펩티드 |
KR20140000620A (ko) | 2010-05-28 | 2014-01-03 | 꽁빠니 자베 다노느 | 장신경계의 개선을 위한 프로바이오틱 균주의 용도 |
KR20150095717A (ko) * | 2012-12-18 | 2015-08-21 | 꽁빠니 자베 다노느 | 비피도박테리움 아니말리스 아종 아니말리스 균주 |
KR101992345B1 (ko) * | 2017-12-29 | 2019-09-27 | (주)메디톡스 | 프로모터 폴리뉴클레오티드, 신호 폴리펩티드 및 그의 용도 |
CN108753670A (zh) | 2018-05-28 | 2018-11-06 | 西北工业大学 | 多功能复合微生态制剂纳米硒-重组表达血管活性肠肽-乳酸乳球菌及制备方法 |
Non-Patent Citations (2)
Title |
---|
See also references of EP4144847A4 |
ZHANG ET AL.: "D-Ala-D-Ala ligase as a broad host-range counterselection marker in vancomycin resistant lactic acid bacteria", J. BACTERIOL., 2018 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096123A1 (ja) * | 2022-11-04 | 2024-05-10 | 株式会社バイオパレット | 遺伝子が改変された微生物およびその生産方法 |
Also Published As
Publication number | Publication date |
---|---|
EP4144847A1 (en) | 2023-03-08 |
KR20210129516A (ko) | 2021-10-28 |
EP4144847A4 (en) | 2024-04-24 |
CA3180666A1 (en) | 2021-10-28 |
CN115916982A (zh) | 2023-04-04 |
AU2021258959A1 (en) | 2022-11-17 |
JP2023523214A (ja) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4989490B2 (ja) | 腸内細菌による生物活性物質の制御された産生および送達 | |
CN103562390B (zh) | 用于细菌的多顺反子表达系统 | |
US11696931B2 (en) | Bacteria for targeting tumors and treating cancer | |
US11725183B2 (en) | Method of culturing segmented filamentous bacteria in vitro | |
WO2021215717A1 (ko) | 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도 | |
JP2024047590A (ja) | Il-10およびインスリンを安定的に発現する遺伝子改変された細菌 | |
US20150216932A1 (en) | Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders | |
WO2020139014A9 (ko) | 외래 단백질을 발현하는 미생물, 및 그의 용도 | |
US8338162B2 (en) | Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium | |
US20230321211A1 (en) | Genetically engineered live bacteria and methods of constructing the same | |
WO2024025315A1 (ko) | Vc1 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21793347 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3180666 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022563907 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021793347 Country of ref document: EP Effective date: 20221102 |
|
ENP | Entry into the national phase |
Ref document number: 2021258959 Country of ref document: AU Date of ref document: 20210409 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |